证券代码：688265 证券简称：南模生物 公告编号：2023-030 上海南方模式生物科技股份有限公司 关于回购股份事项前十名股东和前十名无限售条件股东 持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海南方模式生物科技股份有限公司（以下简称"公司"）于 2023 年 8 月 30 日召开第三届董事会第九次会议，审议通过了《关于以集中竞价交易方式回购 股份方案的议案》，具体内容详见公司于 2023 年 8 月 31 日在上交所网站 （www.sse.com.cn）披露的《关于以集中竞价交易方式回购股份方案的公告》 （公告编号：2023-029）。 P A G E | 10 | 中国工商银行股份有限公司－融通健康产业灵 550,000 0.71 | | --- | --- | | | 活配置混合型证券投资基金 | 二、公司前十名无限售条件股东持股情况 | 序号 | 持有人名称 | 总持有数量 | 占无限售条件流 | | --- | --- | --- | --- | | | | （股） | 通股比例（%） ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2023, representing a year-on-year increase of 20%[1]. - The company expects a revenue guidance of RMB 220 million for the full year 2023, indicating a projected growth of 25% compared to 2022[1]. - The company's operating revenue for the first half of 2023 was ¥180,775,257.15, representing a year-on-year increase of 39.05% compared to ¥130,004,584.97 in the same period last year[19]. - The company reported a total revenue of 35,800 million RMB for the first half of 2023, with a net profit of 3,926.74 million RMB, representing a year-on-year increase of 25,900.44 million RMB[58]. - The company's main business revenue for the first half of 2023 reached 180.25 million CNY, a year-on-year increase of 39.51%[78]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching a total of 1.5 million users by June 30, 2023[1]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2024[1]. - The company is actively exploring overseas markets while consolidating its domestic market share, resulting in increased sales team expenses and travel costs[21]. - The company is expanding its market presence in oncology and immunology, successfully entering the U.S. market with immune-deficient mouse models[79]. Research and Development - The company has invested RMB 10 million in R&D for new technologies aimed at improving product efficiency and reducing costs[1]. - The research and development expenditure accounted for 21.72% of operating revenue, an increase of 3.71 percentage points from 18.01% in the previous year[20]. - The company has developed over 17,000 genetic modification animal models, with more than 10,000 standardized models for drug development[28]. - The company has developed a transgenic mouse model that allows for conditional expression of target genes, enhancing research capabilities[50]. - The company has established a comprehensive gene-modified animal model R&D system and core technology platform, enhancing its service capabilities[42]. Financial Health and Risks - The net profit attributable to shareholders of the listed company decreased by 159.45% to -¥2,903,697.47, down from ¥4,884,254.73 in the previous year[21]. - The net cash flow from operating activities was -¥19,038,077.93, an improvement from -¥33,252,222.31 in the same period last year[19]. - The company faces risks related to the potential decline in the biopharmaceutical investment environment, which could lead to reduced orders and ongoing losses[84]. - There is a risk of technological obsolescence in gene editing techniques, which could impact the company's ability to adapt and innovate[85]. Sustainability and Environmental Initiatives - A commitment to sustainability initiatives was reiterated, with plans to reduce carbon emissions by 15% by 2025[1]. - The company has established an environmental management system and has not faced any administrative penalties related to environmental issues during the reporting period[122]. - The company actively promotes energy conservation and emission reduction, implementing measures such as low-carbon energy use and resource recycling[124]. - The company has implemented a paperless office policy, significantly reducing paper consumption[124]. Corporate Governance and Shareholder Commitments - The controlling shareholder, Tishi Consulting, committed to not transferring or entrusting the management of shares held before the IPO for 36 months from the listing date[137]. - The actual controller and chairman, Fei Jian, pledged to not transfer shares held before the IPO for 36 months from the listing date[130]. - The company has established a commitment to disclose control arrangements after the lock-up period ends[134]. - The company will ensure that any related transactions are priced at market-recognized reasonable prices to avoid harming minority shareholders[174]. Investment and Fund Utilization - The company has committed to invest up to RMB 65 million in the Shanghai Haiwang Medical Health Industry Private Fund, representing approximately 6.47% of the fund's total size of RMB 1.005 billion[184]. - The cumulative investment of the company from its initial public offering (IPO) as of the report date is RMB 1.387 billion, achieving a progress rate of 94.51% against the total commitment of RMB 1.468 billion[189]. - The company plans to use 320 million RMB of its excess raised funds for permanent working capital supplementation[195]. - The company has achieved a production capacity of 100 million RMB for its biopharmaceutical research and development projects[191].

证券代码：688265 证券简称：南模生物 公告编号：2023-025 2、回购股份的方式：集中竞价交易方式 3、回购股份的期限：自公司董事会审议通过回购方案之日起 12 个月内 上海南方模式生物科技股份有限公司 关于收到公司董事长提议回购公司股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海南方模式生物科技股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日收到公司董事长费俭先生《关于上海南方模式生物科技股份有限公司回购公 司股份的提议函》。提议内容主要如下： 一、提议回购股份的原因和目的 提议人费俭先生基于对公司未来发展的信心和对公司价值的认可，为了维 护广大投资者利益，增强投资者对公司的投资信心；同时为了完善公司长效激 励机制，调动公司员工的积极性，将股东利益、公司利益和员工利益紧密结合 在一起，促进公司健康可持续发展。根据相关法律法规，费俭先生提议公司以 集中竞价交易方式回购部分社会公众股份。 二、提议内容 1、回购股份的种类：公司发行的人民币普通股（A 股） 4、回购股份的资金来 ...

证券代码：688265 证券简称：南模生物 公告编号：2023-021 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 公司已于 2023 年 4 月 28 日发布公司《2022 年年度报告》《2023 年第一季 度报告》，为便于广大投资者更全面深入地了解公司 2022 年度和 2023 年第一季 度经营成果、财务状况，公司计划于 2023 年 6 月 14 日下午 15:00-16:00 举行 2022 年度暨 2023 年第一季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2022 年度和 2023 年第一 季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披 露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 1、会议召开时间：2023 年 6 月 14 日下午 15: ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥87,304,768.91, representing a year-on-year increase of 20.08%[5] - The net profit attributable to shareholders was a loss of ¥14,231,619.55, reflecting a decline of 202.22% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥18,252,406.90, down 302.52% year-on-year[5] - Total operating revenue for Q1 2023 was CNY 87,304,768.91, an increase of 20.1% compared to CNY 72,706,319.65 in Q1 2022[21] - Net profit for Q1 2023 was a loss of CNY 14,231,619.55, compared to a profit of CNY 13,921,971.48 in Q1 2022[22] - The company reported a basic and diluted earnings per share of CNY -0.18 for Q1 2023, down from CNY 0.18 in Q1 2022[23] Expenses and Costs - Research and development expenses totaled ¥19,799,024.04, which is an increase of 73.02% compared to the previous year, accounting for 22.68% of operating revenue[6] - Total operating costs for Q1 2023 were CNY 101,776,392.04, up 65.5% from CNY 61,443,743.53 in Q1 2022[21] - Selling expenses rose to CNY 11,165,270.92 in Q1 2023, an increase of 49.5% from CNY 7,444,389.92 in Q1 2022[22] - The increase in management expenses was attributed to significant stock incentive costs and higher administrative staff salaries following the acquisition of Zhongyingjian[10] - The company experienced a significant increase in financial expenses, reporting CNY 652,480.86 in Q1 2023, compared to a gain of CNY -2,204,395.63 in Q1 2022[22] Cash Flow - The company reported a negative cash flow from operating activities of ¥33,872,953.18, which is not applicable for year-on-year comparison[5] - In Q1 2023, the company reported cash inflows from operating activities of ¥66,448,951.40, an increase of 31.9% compared to ¥50,345,556.32 in Q1 2022[24] - The cash outflows from operating activities totaled ¥100,321,904.58, up from ¥70,925,883.82 in the same period last year, resulting in a net cash flow from operating activities of -¥33,872,953.18[24] - The company achieved cash inflows from investment activities of ¥885,839,718.79, significantly higher than ¥527,414,596.75 in Q1 2022, with a net cash flow from investment activities of ¥31,629,037.84[25] - The company reported a net decrease in cash and cash equivalents of -¥8,743,172.73, compared to a much larger decrease of -¥1,309,037,546.86 in Q1 2022[25] - The ending balance of cash and cash equivalents was ¥358,699,458.77, compared to ¥256,106,060.25 in the same quarter last year[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,053,201,079.68, a slight decrease of 0.02% from the end of the previous year[6] - The company's total liabilities as of Q1 2023 were CNY 296,880,628.50, compared to CNY 287,751,134.70 in the previous year[19] - The total equity attributable to shareholders was CNY 1,756,320,451.18, a slight decrease from CNY 1,765,926,830.82 in Q1 2022[19] - The company reported accounts receivable of RMB 138,422,312.72, an increase from RMB 92,636,686.51 year-over-year[17] - The company’s fixed assets are valued at RMB 118,640,906.99, a slight decrease from RMB 119,807,372.24[17] - The company’s non-current assets total RMB 814,749,046.94, up from RMB 793,021,392.26 year-over-year[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,229[12] - The largest shareholder, Shanghai Dish Consulting, holds 27,771,000 shares, representing 35.62% of total shares[12] Market and Expansion - The company is actively expanding its domestic and overseas markets, increasing its sales team to enhance market share[10] - The company expanded its production capacity from 100,000 cages to 140,000 cages, leading to increased costs in depreciation, materials, and labor[9] Other Information - The company has no reported new products or technologies, market expansions, or mergers during this reporting period[15] - The company did not report any net profit from the merged entity prior to the merger, consistent with the previous period[24] - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the current year[26]

2022年年度报告摘要 公司代码：688265 公司简称：南模生物 上海南方模式生物科技股份有限公司 2022 年年度报告摘要 2022年年度报告摘要 第一节 重要提示 1 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到www.sse.com.cn网站仔细阅读年度报告全文。 2 重大风险提示 本公司已在本报告中详细阐述在生产经营过程中可能面临的相关风险,详情敬请查阅本报告 “第三节 管理层讨论与分析”之“四 风险因素”部分的相关内容。 3 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 4 公司全体董事出席董事会会议。 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥85,440,761.93, representing a year-on-year increase of 25.78%[5] - The net profit attributable to shareholders was -¥4,959,326.26, a decrease of 108.15% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥12,643,704.76, reflecting a decline of 124.09%[6] - Basic earnings per share for the current reporting period was -105.77, with diluted earnings per share also at -105.77, reflecting a decrease in net profit[11] - The net profit for Q3 2022 was -75,071.53 RMB, a significant decrease compared to 38,727,634.07 RMB in Q3 2021[25] - The total profit for Q3 2022 was -3,737,828.96 RMB, down from 43,878,279.60 RMB in the same period last year[25] - Operating profit for Q3 2022 was -3,594,726.72 RMB, compared to 44,123,180.62 RMB in Q3 2021[25] - The total comprehensive income for Q3 2022 was 356,678.47 RMB, down from 38,725,802.05 RMB in Q3 2021[26] - Basic and diluted earnings per share for Q3 2022 were both 0.00 RMB, compared to 0.66 RMB in Q3 2021[26] Research and Development - The total R&D investment amounted to ¥21,544,964.23, which accounted for 25.22% of operating revenue, an increase of 4.82 percentage points year-on-year[6] - Total R&D investment for the current reporting period was 55.48 million, an increase from 32.78 million for the year-to-date[11] - Research and development expenses for the first three quarters of 2022 amounted to CNY 44,957,893.67, compared to CNY 33,859,549.58 in 2021, reflecting a year-over-year increase of approximately 32.7%[23] - The company is focusing on expanding its research and development efforts, as evidenced by the increased R&D expenses, which may lead to new product developments in the future[23] Cash Flow and Assets - The cash flow from operating activities was -¥17,163,740.37, indicating a significant decline of 133.77%[6] - The company's cash and cash equivalents decreased to CNY 251,303,400.28 from CNY 1,566,200,232.11, a decline of about 84%[18] - Cash flow from operating activities for the first nine months of 2022 was -17,163,740.37 RMB, a decline from 50,820,389.56 RMB in the same period of 2021[29] - Cash flow from investment activities in the first nine months of 2022 was -1,057,536,533.39 RMB, compared to a positive cash flow of 21,708.78 RMB in the previous year[29] - The cash and cash equivalents at the end of Q3 2022 were 251,278,400.28 RMB, a decrease from 115,526,472.92 RMB at the end of Q3 2021[30] - The company reported a cash inflow from operating activities of 190,703,456.29 RMB for the first nine months of 2022, down from 202,626,670.51 RMB in the same period of 2021[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,008[13] - The largest shareholder, Shanghai Dish Consulting Co., Ltd., holds 27,771,000 shares, representing 35.6% of total shares[13] - The second-largest shareholder, Shanghai Technology Venture Capital Co., Ltd., holds 10,760,733 shares, accounting for 13.8%[13] Operational Challenges - The company faced challenges in revenue growth due to the impact of COVID-19 control measures in Shanghai, affecting new orders and revenue recognition[10] - The company's operating revenue growth was low due to COVID-19 control measures in Shanghai, leading to a decrease in cash inflow from operating activities[11] - The company is facing uncertainties in its external operating environment due to the ongoing impact of COVID-19, which may affect logistics and transportation[16] - The company has implemented enhanced epidemic prevention measures and emergency plans to mitigate the adverse effects of COVID-19[17] Costs and Liabilities - Total operating costs for the first three quarters of 2022 were CNY 234,245,219.39, up from CNY 150,123,769.13 in 2021, indicating a significant increase of about 56%[23] - Total liabilities as of September 30, 2022, were CNY 368,227,444.67, up from CNY 180,396,846.80 in 2021, which is an increase of approximately 103.5%[20] - The company's inventory as of September 30, 2022, was CNY 14,674,652.20, slightly down from CNY 15,011,078.34 in 2021, indicating a decrease of about 2.2%[18] - The non-current assets totaled CNY 676,689,973.38 as of September 30, 2022, compared to CNY 203,350,577.75 at the end of 2021, representing a significant increase of approximately 232%[19] Production Capacity - The company expanded its production capacity from 50,000 cages to 110,000 cages, leading to increased costs in depreciation and material expenses[10] - Management expenses increased significantly due to the new Shanghai Novartis base being in the renovation and trial operation phase, resulting in high rental and utility costs[10]

Financial Performance - The company plans not to distribute profits for the year 2022, with no cash dividends or stock bonuses, and will carry forward the undistributed profits to the next year[7]. - The company has not achieved profitability since its listing[5]. - The company's operating revenue for 2022 was CNY 302,965,239.57, representing a year-on-year increase of 10.06%[25]. - The net profit attributable to shareholders decreased by 108.87% to a loss of CNY 5,399,643.49[28]. - The net cash flow from operating activities was CNY 18,893,416.66, down 83.05% compared to the previous year[29]. - Basic and diluted earnings per share fell to -CNY 0.07, a decrease of 106.73%[30]. - The company reported a total revenue of 30,242.88 million yuan for its main business in 2022, representing a year-on-year growth of 10.52%[57]. - The net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was approximately CNY -29.56 million, a year-on-year decrease of 156.33%[41]. - The company achieved a 68.19% year-on-year increase in overseas revenue, amounting to 32.69 million yuan, despite challenges from COVID-19 and high temperatures affecting air freight[52]. Risk Management - The company has detailed the potential risks faced during its operations in the report[5]. - The company has a comprehensive risk statement regarding forward-looking statements in the annual report[8]. - There are no non-operating fund occupations by controlling shareholders or related parties[9]. - The company is exposed to regulatory risks related to the management of experimental animals, especially as regulations become stricter[128]. - The company faces risks related to changes in tax incentives and government subsidy policies, which could adversely affect profitability[131]. - The company must maintain high-quality standards and stable product quality to meet the dynamic demands of clients, as customer loyalty is high for verified strains[76]. Research and Development - Research and development expenses accounted for 21.7% of operating revenue, an increase of 4.28 percentage points from the previous year[26]. - R&D expenses totaled 65.76 million yuan, a year-on-year increase of 37.14%, contributing to a decline in profits for the period[44]. - The company has developed over 15,000 models, including more than 8,600 standardized models, showcasing its extensive experience in gene-modified animal model development[60]. - The company has developed four core technologies in gene-modified animal model construction, including CRISPR/Cas system gene editing technology and ES cell targeting technology[92]. - The company is focused on optimizing CRISPR/Cas and ES cell targeting techniques to improve animal model quality[98]. - The company is committed to optimizing gene editing parameters to improve success rates and reduce off-target risks, while exploring multi-gene modification techniques[191]. Market Expansion - The company is expanding its market presence in Europe, targeting a 15% market share by the end of 2023[18]. - The company is actively expanding its sales channels, establishing offices in Europe and Japan, and collaborating with distributors in Singapore and South Korea to enhance its international presence[52]. - The company plans to enhance its domestic market share and expand its international market presence through increased sales team investments[28]. - The company is deepening its domestic market presence while accelerating its global expansion, particularly in Europe and the U.S.[194]. Corporate Governance - The audit report issued by Zhonghui Certified Public Accountants is a standard unqualified opinion[6]. - The financial report is confirmed to be true, accurate, and complete by the responsible persons[7]. - The company has not implemented any special arrangements for corporate governance[10]. Operational Efficiency - The gross margin improved to 60%, up from 55% in the previous year, reflecting better operational efficiency[16]. - The company faced increased production costs due to expanded scale and rising expenses in materials, energy, and labor[28]. - The company reported significant increases in management and sales expenses due to expansion efforts and rising operational costs[28]. - The company expanded its production capacity to approximately 140,000 cage positions across five production and R&D bases[28]. Strategic Acquisitions - A strategic acquisition of a smaller biotech firm was completed, enhancing the company's R&D capabilities and expected to generate $5 million in cost synergies[14]. - The company acquired 100% equity of Zhongyingjian through a debt acquisition, focusing on core assets related to industrial land and facilities[33]. - The company completed the acquisition of 100% equity in Shanghai Zhongying Health Technology Co., Ltd. for RMB 395.73 million using raised funds, with the business registration change completed by the end of the reporting period[179]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 30%[16]. - Future guidance includes an EBITDA margin target of 25% for the upcoming fiscal year[18]. - The company plans to enhance market development efforts and improve project completion efficiency to restore revenue growth as external uncertainties decrease[58].

1 证券代码：688265 证券简称：南模生物 上海南方模式生物科技股份有限公司 投资者关系活动记录表 编号：2022-005 | --- | --- | --- | |------------|--------------------------|-------| | | 特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系 | □新闻发布会 □路演活动 | | | 活动类别 | □现场参观 | | | --- | --- | |----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

1 证券代码：688265 证券简称：南模生物 上海南方模式生物科技股份有限公司 投资者关系活动记录表 编号：2022-004 | --- | --- | --- | |--------------|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...